Cargando…

Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease

Background: Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Armandi, Angelo, Rosso, Chiara, Nicolosi, Aurora, Caviglia, Gian Paolo, Abate, Maria Lorena, Olivero, Antonella, D’Amato, Daphne, Vernero, Marta, Gaggini, Melania, Saracco, Giorgio Maria, Ribaldone, Davide Giuseppe, Leeming, Diana Julie, Gastaldelli, Amalia, Bugianesi, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837035/
https://www.ncbi.nlm.nih.gov/pubmed/35160087
http://dx.doi.org/10.3390/jcm11030635
_version_ 1784649825394884608
author Armandi, Angelo
Rosso, Chiara
Nicolosi, Aurora
Caviglia, Gian Paolo
Abate, Maria Lorena
Olivero, Antonella
D’Amato, Daphne
Vernero, Marta
Gaggini, Melania
Saracco, Giorgio Maria
Ribaldone, Davide Giuseppe
Leeming, Diana Julie
Gastaldelli, Amalia
Bugianesi, Elisabetta
author_facet Armandi, Angelo
Rosso, Chiara
Nicolosi, Aurora
Caviglia, Gian Paolo
Abate, Maria Lorena
Olivero, Antonella
D’Amato, Daphne
Vernero, Marta
Gaggini, Melania
Saracco, Giorgio Maria
Ribaldone, Davide Giuseppe
Leeming, Diana Julie
Gastaldelli, Amalia
Bugianesi, Elisabetta
author_sort Armandi, Angelo
collection PubMed
description Background: Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Additionally, pre-clinical models have shown a potential role of irisin in the pathogenesis of NAFLD. The aim of this study is to explore the association between irisin, histological features and biomarkers of liver fibrogenesis in non-diabetic, non-obese, biopsy-proven NAFLD individuals. Methods: Forty-one patients with histological evidence of NAFLD were included. Circulating irisin and direct markers of fibrogenesis N-terminal type III collagen propeptide (PRO-C3) and type VI collagen cleavage product (PRO-C6) were measured by ELISA. Results: Median age of the cohort was 45 years (41–51) and 80.4% were male. Significant fibrosis (stage ≥ 2) was present in 36.6% of cases. Circulating irisin, PRO-C3 and PRO-C6 levels were significantly higher in subjects with fibrosis stage ≥ 2 when compared to those with fibrosis stage < 2 (5.96 ng/mL (95% CI = 4.42–9.19) vs. 2.42 ng/mL (95% CI = 1.73–5.95), p = 0.033; 9.5 ng/mL (95% CI = 7.7–13.6) vs. 6.2 ng/mL (95% CI = 4.9–8.9), p = 0.016; 6.6 ng/mL (95% CI = 5.6–7.9) vs. 5.1 ng/mL (95% CI = 4.2–5.4), p = 0.013, respectively). Irisin levels were similarly distributed between the features of NASH. Circulating irisin positively correlated with both PRO-C3 and PRO-C6 levels (r = 0.47, p = 0.008 and r = 0.46, p = 0.002). Conclusions: Increased circulating irisin levels may identify a more aggressive phenotype of liver disease with increased fibrogenesis and more severe liver damage.
format Online
Article
Text
id pubmed-8837035
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88370352022-02-12 Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease Armandi, Angelo Rosso, Chiara Nicolosi, Aurora Caviglia, Gian Paolo Abate, Maria Lorena Olivero, Antonella D’Amato, Daphne Vernero, Marta Gaggini, Melania Saracco, Giorgio Maria Ribaldone, Davide Giuseppe Leeming, Diana Julie Gastaldelli, Amalia Bugianesi, Elisabetta J Clin Med Article Background: Insulin resistance plays a relevant role in the onset of non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and fibrosis. Irisin is an exercise-induced myokine involved in the regulation of energy homeostasis and glucose metabolism. Additionally, pre-clinical models have shown a potential role of irisin in the pathogenesis of NAFLD. The aim of this study is to explore the association between irisin, histological features and biomarkers of liver fibrogenesis in non-diabetic, non-obese, biopsy-proven NAFLD individuals. Methods: Forty-one patients with histological evidence of NAFLD were included. Circulating irisin and direct markers of fibrogenesis N-terminal type III collagen propeptide (PRO-C3) and type VI collagen cleavage product (PRO-C6) were measured by ELISA. Results: Median age of the cohort was 45 years (41–51) and 80.4% were male. Significant fibrosis (stage ≥ 2) was present in 36.6% of cases. Circulating irisin, PRO-C3 and PRO-C6 levels were significantly higher in subjects with fibrosis stage ≥ 2 when compared to those with fibrosis stage < 2 (5.96 ng/mL (95% CI = 4.42–9.19) vs. 2.42 ng/mL (95% CI = 1.73–5.95), p = 0.033; 9.5 ng/mL (95% CI = 7.7–13.6) vs. 6.2 ng/mL (95% CI = 4.9–8.9), p = 0.016; 6.6 ng/mL (95% CI = 5.6–7.9) vs. 5.1 ng/mL (95% CI = 4.2–5.4), p = 0.013, respectively). Irisin levels were similarly distributed between the features of NASH. Circulating irisin positively correlated with both PRO-C3 and PRO-C6 levels (r = 0.47, p = 0.008 and r = 0.46, p = 0.002). Conclusions: Increased circulating irisin levels may identify a more aggressive phenotype of liver disease with increased fibrogenesis and more severe liver damage. MDPI 2022-01-27 /pmc/articles/PMC8837035/ /pubmed/35160087 http://dx.doi.org/10.3390/jcm11030635 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Armandi, Angelo
Rosso, Chiara
Nicolosi, Aurora
Caviglia, Gian Paolo
Abate, Maria Lorena
Olivero, Antonella
D’Amato, Daphne
Vernero, Marta
Gaggini, Melania
Saracco, Giorgio Maria
Ribaldone, Davide Giuseppe
Leeming, Diana Julie
Gastaldelli, Amalia
Bugianesi, Elisabetta
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
title Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
title_full Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
title_fullStr Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
title_full_unstemmed Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
title_short Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease
title_sort crosstalk between irisin levels, liver fibrogenesis and liver damage in non-obese, non-diabetic individuals with non-alcoholic fatty liver disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837035/
https://www.ncbi.nlm.nih.gov/pubmed/35160087
http://dx.doi.org/10.3390/jcm11030635
work_keys_str_mv AT armandiangelo crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT rossochiara crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT nicolosiaurora crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT cavigliagianpaolo crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT abatemarialorena crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT oliveroantonella crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT damatodaphne crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT verneromarta crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT gagginimelania crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT saraccogiorgiomaria crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT ribaldonedavidegiuseppe crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT leemingdianajulie crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT gastaldelliamalia crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease
AT bugianesielisabetta crosstalkbetweenirisinlevelsliverfibrogenesisandliverdamageinnonobesenondiabeticindividualswithnonalcoholicfattyliverdisease